<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Omega</journal-id><journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id><journal-id journal-id-type="publisher-id">ao</journal-id><journal-id journal-id-type="coden">acsodf</journal-id><journal-title-group><journal-title>ACS Omega</journal-title></journal-title-group><issn pub-type="epub">2470-1343</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8015128</article-id><article-id pub-id-type="doi">10.1021/acsomega.1c00366</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Antileishmanial Evaluation of Bark Methanolic Extract
of <italic>Acacia nilotica</italic>: <italic>In Vitro</italic> and <italic>In Silico</italic> Studies</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Ali</surname><given-names>Rahat</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Tabrez</surname><given-names>Shams</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Rahman</surname><given-names>Fazlur</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes3" ref-type="notes">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Alouffi</surname><given-names>Abdulaziz S.</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Alshehri</surname><given-names>Bader M.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Alshammari</surname><given-names>Fahdah Ayed</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Alaidarous</surname><given-names>Mohammed A.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Banawas</surname><given-names>Saeed</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x022a5;</xref><xref rid="aff6" ref-type="aff">#</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>Dukhyil</surname><given-names>Abdul Aziz Bin</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath10"><name><surname>Rub</surname><given-names>Abdur</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Infection
and Immunity Laboratory (414), Department of Biotechnology, <institution>Jamia Millia Islamia (A Central University)</institution>, New Delhi 110025, <country>India</country></aff><aff id="aff2"><label>&#x02021;</label><institution>King
Abdulaziz City for Science and Technology</institution>, Riyadh 12354, <country>Saudi Arabia</country></aff><aff id="aff3"><label>&#x000a7;</label>College
of Applied Medical Sciences, <institution>Majmaah University</institution>, Al Majmaah, Al-Majma&#x02019;ah 11952, <country>Saudi Arabia</country></aff><aff id="aff4"><label>&#x02225;</label>College
of Sciences and Literature Microbiology, <institution>Northern Border University</institution>, Arar 73222, <country>Saudi Arabia</country></aff><aff id="aff5"><label>&#x022a5;</label>Deanship
of Scientific Research, <institution>Majmaah University</institution>, Al Majmaah, Al Majma&#x02019;ah 11952, <country>Saudi Arabia</country></aff><aff id="aff6"><label>#</label>Department
of Biomedical Sciences, <institution>Oregon State University</institution>, Corvallis, Oregon 97331, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>arub@jmi.ac.in</email>. Phone: <phone>+91-9560887383</phone>.</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><day>30</day><month>03</month><year>2021</year></pub-date><volume>6</volume><issue>12</issue><fpage>8548</fpage><lpage>8560</lpage><history><date date-type="received"><day>20</day><month>01</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>03</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; 2021 The
Authors. Published by American
Chemical Society</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Authors</copyright-holder><license license-type="open-access"><license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0008" id="ab-tgr1"/></p><p><italic>Acacia
nilotica</italic> (<italic>A. nilotica)</italic> is an important medicinal plant, found
in Africa, the Middle East, and the Indian subcontinent. Every part
of the plant possesses a wide array of biologically active and therapeutically
important compounds. We reported the antileishmanial activity of <italic>A. nilotica</italic> bark methanolic extract through <italic>in vitro</italic> antileishmanial assays and dissected the mechanism
of its action through <italic>in silico</italic> studies. Bark methanolic
extract exhibited antipromastigote and antiamastigote potential in
a time and dose-dependent manner with IC<sub>50</sub> values of 19.6
&#x000b1; 0.9037 and 77.52 &#x000b1; 5.167 &#x003bc;g/mL, respectively. It
showed cytotoxicity on THP-1-derived human macrophages at very high
dose with a CC<sub>50</sub> value of 432.7 &#x000b1; 7.71 &#x003bc;g/mL.
The major constituents identified by gas chromatography&#x02013;mass
spectrometry (GC&#x02013;MS) analysis, 13-docosenoic acid, lupeol,
9,12-octadecadienoic acid, and 6-octadecanoic acid, showed effective
binding with the potential drug targets of <italic>Leishmania
donovani</italic> (<italic>L. donovani</italic>) including sterol 24-<italic>c</italic>-methyltransferase, trypanothione
reductase, pteridine reductase, and adenine phosphoribosyltransferase,
suggesting the possible mechanism of its antileishmanial action. Pharmacokinetic
studies on major phytoconstituents analyzed by GC&#x02013;MS supported
their use as safe antileishmanial drug candidates. This study proved
the antileishmanial potential of bark methanolic extract <italic>A. nilotica</italic> and its mechanism of action through the
inhibition of potential drug targets of <italic>L. donovani</italic>.</p></abstract><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ao1c00366</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ao1c00366</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p>Visceral
leishmaniasis (VL), also known as kala-azar in the Indian
subcontinent, is a fatal form of the vector-borne disease caused by
protozoan parasite <italic>Leishmania donovani</italic>. The disease remained endemic in more than 88 countries around the
globe, while 95% of cases are concentrated in 7&#x02013;8 countries.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> More than 50% of the global burden of VL is found
in the Indian subcontinent (India, Bangladesh, and Nepal).<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> The disease is proved to be fatal if left untreated in more than
95% of cases because of secondary infection and anemia.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> VL is ranked second in the mortality rate among
the neglected tropical diseases.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref6">6</xref></sup> It is a significant
problem for the economically weaker section of the society. Due to
their unhygienic living environment, they are more vulnerable to the
disease.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Illiteracy is another factor
that is directly proportional to the lack of awareness which led to
major morbidity and mortality. The available chemotherapy of VL is
limited and undermined by drug resistance. Currently, in general,
the drug used in the Indian subcontinent sodium antimony gluconate
showed no response in more than 64% of the patients due to the development
of resistance against the parasites.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Miltefosine,
amphotericin B, and its lipid formulations have several limitations
because of high toxicity, cost, and unavailability, which limit their
use. The present scenario of disease and its limited treatment options
demand an urgent need to develop a promising and cost-effective operational
drug to overcome the disease. To date, a large number of medicinal
plants and their extracts had been studied for antileishmanial activity
and proved to be potential therapeutic options.<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> Here,
we planned to explore the antileishmanial activity of the medicinal
plant, <italic>Acacia nilotica</italic>. <italic>A. nilotica</italic> is commonly known as babul and belongs
to the family Fabaceae of genus <italic>Acacia</italic>. It is an important medicinal plant, found in Africa, the Middle
East, and the Indian subcontinent.<sup><xref ref-type="bibr" rid="ref11">11</xref>&#x02212;<xref ref-type="bibr" rid="ref13">13</xref></sup> It is rich in secondary
metabolites including condensed tannins, flavonoids, gums, and phlobatannins.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> Every part of the plant possesses a wide array of biologically active,
therapeutically potential compounds that are used in the traditional
system of medicine as a remedy for various diseases. Its different
parts are used in the treatment of different diseases such as floral
parts for gastrointestinal disorders,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> leaf extracts for cancer and microbial infections,<sup><xref ref-type="bibr" rid="ref17">17</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup> root extracts for tuberculosis and liver disorders,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and bark for bacterial infections including cold, bronchitis,
dysentery, biliousness, cholera, and bleeding piles.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref20">20</xref>&#x02212;<xref ref-type="bibr" rid="ref22">22</xref></sup> Keeping the rich antimicrobial bioactive collection
of the bark of <italic>A. nilotica</italic>, in mind,
we planned to study its antileishmanial potential here. We also tried
to dissect the mechanism of its antileishmanial action through different <italic>in silico</italic> approaches. Sterol 24-<italic>c</italic>-methyltransferase
(SMT), trypanothione reductase (TR), pteridine reductase (PTR1), and
adenine phosphoribosyltransferase (APRT) are prerequisite enzymes
for survival, pathogenicity, and transmission of <italic>L.
donovani</italic>. Therefore, we selected these potential drug
targets for the molecular docking study of major constituents of bark
extract identified by gas chromatography&#x02013;mass spectrometry
(GC&#x02013;MS), with these mentioned potential drug targets of <italic>Leishmania</italic>.</p></sec><sec id="sec2"><label>2</label><title>Results</title><sec id="sec2.1"><label>2.1</label><title>Antileishmanial
Activity of <italic>A. nilotica</italic> on <italic>L. donovani</italic> Promastigotes</title><p>The growth inhibitory
effects of the <italic>A. nilotica</italic> bark methanolic
extract fraction were
assessed against exponentially growing <italic>L. donovani</italic> promastigotes. <italic>A. nilotica</italic> treatment
reduced the promastigote proliferation in a time and dose-dependent
manner. Growth kinetics was assessed for 7 days; there was a gradual
decrease in the promastigote proliferation at all the doses (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>a). The promastigote
culture was completely shattered at the dose concentrations of 250
and 500 &#x003bc;g/mL of <italic>A. nilotica</italic> after
3 days of treatment. Miltefosine, an established antileishmanial drug,
rapidly shattered the promastigote parasites <italic>in vitro</italic>. The <italic>Leishmania</italic> promastigotes, without
any treatment or with 0.5% dimethyl sulfoxide (DMSO) (solvent control),
exponentially grow till the 4th day of parasite seeding, conforming
to no antileishmanial potential of the solvent. After the 4th day
of the experimental setup, the culture even in the control and the
solvent control gradually decreased because of media exhaustion. The
IC<sub>50</sub> value of <italic>A. nilotica</italic> on <italic>Leishmania</italic> promastigotes was calculated
as 19.6 &#x000b1; 0.9037 &#x003bc;g/mL, and the miltefosine-treated positive
control has an IC<sub>50</sub> of 3.118 &#x000b1; 0.2395 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>b). <italic>A. nilotica</italic> treatment exhibits the morphological changes in the promastigote-stage
parasites, though at lower doses the parasites retained a normal morphology.
At the higher concentrations, there is a reduction in size and shortening
of flagella. Miltefosine treatment also exhibited similar morphological
changes as extract showed at higher doses (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>c).</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p><italic>A. nilotica</italic> bark
methanolic extract
inhibited the growth and proliferation of <italic>L. donovani</italic> promastigotes. (a) 2 &#x000d7; 10<sup>6</sup> stationary phase <italic>L. donovani</italic> promastigotes were treated with different
concentrations of <italic>A. nilotica</italic> methanolic
plant extracts, with miltefosine as the standard drug and control
(without any treatment). (b) 2 &#x000d7; 10<sup>6</sup> stationary phase <italic>L. donovani</italic> promastigotes were treated with different
concentrations of the <italic>A. nilotica</italic> methanolic
plant extract fraction and miltefosine; IC<sub>50</sub> was determined
as described in the Materials and Methods. Each point represented
the mean &#x000b1; SE of the samples in triplicate. (c) Images of the
promastigote showing changes in morphology upon extract and miltefosine
treatment. (d) Stationary phase <italic>L. donovani</italic> promastigotes were incubated with different concentrations of <italic>A. nilotica</italic>, with miltefosine and DMSO (solvent control).
Also, the growth reversal was analyzed as described in Materials and
Methods. <sup>***</sup><italic>P</italic> &#x0003c; 0.001 with respect
to the parasite control. Antipromastigote efficacy of <italic>A. nilotica</italic> fractions.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0002" id="gr1" position="float"/></fig></sec><sec id="sec2.2"><label>2.2</label><title>Growth Reversibility Assay after Extract Treatment</title><p><italic>A. nilotica</italic>-treated and -untreated
parasites were washed with phosphate-buffered saline after 7 days,
and old media were removed and supplemented with fresh media. The
samples were further incubated at 22 &#x000b0;C for the next 72 h to
study the growth reversibility of parasites. Parasites treated with
higher doses do not revert though parasites in flasks of lower dose
plant-extract treatment show slower growth reversion (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>d). Suppression of growth reversion
was observed significantly (<italic>P</italic> &#x0003c; 0.001) at 250
&#x003bc;g/mL of <italic>A. nilotica</italic> in comparison
to the untreated sample (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>d).</p></sec><sec id="sec2.3"><label>2.3</label><title>Cytotoxicity and Antileishmanial
Activity
of <italic>A. nilotica</italic> on Intramacrophagic
Amastigotes</title><p>Upon internalization, promastigotes are transformed
into the amastigote form inside the parasitophorous vacuoles of macrophages.
These amastigote forms of the parasites are nonmotile and define the
parasite pathogenicity. Thus, being the biologically and clinically
relevant form, it was important to check the antiamastigote efficacy
of the <italic>A. nilotica</italic> methanolic extract.
THP-1-differentiated macrophages were parasitized by <italic>L. donovani</italic> promastigotes and treated with different
doses of the extract. Plant extract treatment reduced the intramacrophagic
parasites in a dose-dependent manner with an IC<sub>50</sub> value
of 77.52 &#x000b1; 5.167 &#x003bc;g/mL (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>a). Miltefosine was taken as a positive control
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>a). Cell cytotoxicity
(CC<sub>50</sub>) of <italic>A. nilotica</italic> methanolic
extract was evaluated along with miltefosine as a positive control
on THP-1-differentiated macrophages to study its safe dose. THP-1-differentiated
macrophages were incubated with different concentrations of extract/miltefosine
(0&#x02013;1000 &#x003bc;g/mL), and the cell viability was assessed using
the 3-(4,5 dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay. It was observed that <italic>A. nilotica</italic> has the least cytotoxic effect on the viability and morphology of
the macrophages with a CC<sub>50</sub> value of 432.7 &#x000b1; 7.71
&#x003bc;g/mL, while miltefosine showed higher toxicity with a CC<sub>50</sub> value of 8.219 &#x000b1; 0.6337 &#x003bc;g/mL (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>b). A significant reduction
in the intramacrophagic parasite count was observed in the micrographs
of Giemsa-stained infected and extract-treated macrophages (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>c).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p><italic>A. nilotica</italic> bark methanolic extract
decreased the intramacrophagic parasites. (a) THP-1-differentiated
macrophages were parasitized in with 1:10 ratio promastigotes and
then treated with different concentrations of the <italic>A.
nilotica</italic> fraction. Percent reduction in the parasite
load was determined as described in the Materials and Methods. <sup>***</sup><italic>P</italic> &#x0003c; 0.001 value was statistically significant
as compared to the control. (b) THP-1-differentiated macrophages were
treated with different concentrations of <italic>A. nilotica</italic> and miltefosine (0&#x02013;1000 &#x003bc;g/mL), and cell viability
was ascertained by the MTT assay. (c) Images of Giemsa-stained <italic>L. donovani</italic>-infected macrophages, treated with the
extract and control drug. The images were captured at 100&#x000d7; under
oil immersion. The arrow indicates internalized parasites.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0003" id="gr2" position="float"/></fig></sec><sec id="sec2.4"><label>2.4</label><title>Thin-Layer Chromatography-Bioautography Identification
and GC&#x02013;MS Analysis of <italic>A. nilotica</italic> Bark Methanolic Extract</title><p>Plant secondary metabolites present
in <italic>A. nilotica</italic> bark methanolic extract
fractions that may have been responsible for the observed antileishmanial
effects were identified through thin-layer chromatography (TLC)-bioautography
and GC&#x02013;MS analysis. The total constituents found were 25 (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>), out of which the
major constituents were 13-docosenoic acid (34.06%), lupeol (20.15%),
9,12-octadecadienoic acid (9.92%), and 6-octadecanoic acid (8.43%).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>TLC-Bioautography Identification and
GC&#x02013;MS Analysis of <italic>A. nilotica</italic> Bark Methanolic Extract Depicted Key Chemical Constituents of the
Extract</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">S. no.</th><th style="border:none;" align="center" char=".">retention time</th><th style="border:none;" align="center" char=".">%&#x000a0;area</th><th style="border:none;" align="center">compound identified</th></tr></thead><tbody><tr><td style="border:none;" align="left">1.</td><td style="border:none;" align="char" char=".">13.606</td><td style="border:none;" align="char" char=".">0.45</td><td style="border:none;" align="left">1<italic>H</italic>-3A,7-methanoazulen-6-ol</td></tr><tr><td style="border:none;" align="left">2.</td><td style="border:none;" align="char" char=".">14.220</td><td style="border:none;" align="char" char=".">0.79</td><td style="border:none;" align="left">1<italic>H</italic>-benzocycloheptene</td></tr><tr><td style="border:none;" align="left">3.</td><td style="border:none;" align="char" char=".">14.290</td><td style="border:none;" align="char" char=".">0.32</td><td style="border:none;" align="left">phenol, 3,5-bis(1,1-dimethylethyl)</td></tr><tr><td style="border:none;" align="left">4.</td><td style="border:none;" align="char" char=".">15.277</td><td style="border:none;" align="char" char=".">1.49</td><td style="border:none;" align="left">diethyl phthalate</td></tr><tr><td style="border:none;" align="left">5.</td><td style="border:none;" align="char" char=".">16.139</td><td style="border:none;" align="char" char=".">0.54</td><td style="border:none;" align="left">1-(4-isopropylphenyl)-2-methylpropyl acetate</td></tr><tr><td style="border:none;" align="left">6.</td><td style="border:none;" align="char" char=".">18.855</td><td style="border:none;" align="char" char=".">5.42</td><td style="border:none;" align="left">hexadecanoic acid, methyl ester</td></tr><tr><td style="border:none;" align="left">7.</td><td style="border:none;" align="char" char=".">19.328</td><td style="border:none;" align="char" char=".">1.71</td><td style="border:none;" align="left"><italic>N</italic>-hexadecanoic acid</td></tr><tr><td style="border:none;" align="left">8.</td><td style="border:none;" align="char" char=".">20.258</td><td style="border:none;" align="char" char=".">0.30</td><td style="border:none;" align="left">13-hexyl-oxa-cyclotridec-10-en-2-one</td></tr><tr><td style="border:none;" align="left">9.</td><td style="border:none;" align="char" char="."><bold>20.465</bold></td><td style="border:none;" align="char" char="."><bold>9.92</bold></td><td style="border:none;" align="left"><bold>9,12-octadecadienoic</bold><bold>acid</bold></td></tr><tr><td style="border:none;" align="left">10.</td><td style="border:none;" align="char" char=".">20.523</td><td style="border:none;" align="char" char=".">8.43</td><td style="border:none;" align="left">6-octadecenoic acid, methyl
ester</td></tr><tr><td style="border:none;" align="left">11.</td><td style="border:none;" align="char" char=".">20.761</td><td style="border:none;" align="char" char=".">2.81</td><td style="border:none;" align="left">methyl stearate</td></tr><tr><td style="border:none;" align="left">12.</td><td style="border:none;" align="char" char=".">20.961</td><td style="border:none;" align="char" char=".">1.44</td><td style="border:none;" align="left"><italic>E</italic>,<italic>E</italic>,<italic>Z</italic>-1,3,12-nonadecatriene-5,14-diol</td></tr><tr><td style="border:none;" align="left">13.</td><td style="border:none;" align="char" char=".">22.267</td><td style="border:none;" align="char" char=".">0.17</td><td style="border:none;" align="left">hexahydro-3-butylphthalide</td></tr><tr><td style="border:none;" align="left">14.</td><td style="border:none;" align="char" char=".">22.311</td><td style="border:none;" align="char" char=".">2.86</td><td style="border:none;" align="left"><italic>cis</italic>-11-eicosenoic acid, methyl ester</td></tr><tr><td style="border:none;" align="left">15.</td><td style="border:none;" align="char" char=".">22.368</td><td style="border:none;" align="char" char=".">0.53</td><td style="border:none;" align="left"><italic>cis</italic>-13-eicosenoic acid, methyl ester</td></tr><tr><td style="border:none;" align="left">16.</td><td style="border:none;" align="char" char=".">22.527</td><td style="border:none;" align="char" char=".">1.14</td><td style="border:none;" align="left">eicosanoic acid, methyl ester</td></tr><tr><td style="border:none;" align="left">17.</td><td style="border:none;" align="char" char="."><bold>23.965</bold></td><td style="border:none;" align="char" char="."><bold>34.06</bold></td><td style="border:none;" align="left"><bold>13-docosenoic</bold><bold>acid</bold></td></tr><tr><td style="border:none;" align="left">18.</td><td style="border:none;" align="char" char=".">24.161</td><td style="border:none;" align="char" char=".">0.84</td><td style="border:none;" align="left">docosanoic acid</td></tr><tr><td style="border:none;" align="left">19.</td><td style="border:none;" align="char" char=".">25.532</td><td style="border:none;" align="char" char=".">1.52</td><td style="border:none;" align="left"><italic>cis</italic>-15-tetracosensaeure</td></tr><tr><td style="border:none;" align="left">20.</td><td style="border:none;" align="char" char=".">25.721</td><td style="border:none;" align="char" char=".">0.70</td><td style="border:none;" align="left">tetracosanoic acid</td></tr><tr><td style="border:none;" align="left">21.</td><td style="border:none;" align="char" char=".">25.897</td><td style="border:none;" align="char" char=".">0.85</td><td style="border:none;" align="left">Cyclopentadecanone</td></tr><tr><td style="border:none;" align="left">22.</td><td style="border:none;" align="char" char=".">27.325</td><td style="border:none;" align="char" char=".">0.34</td><td style="border:none;" align="left">Octacosane</td></tr><tr><td style="border:none;" align="left">23.</td><td style="border:none;" align="char" char=".">27.885</td><td style="border:none;" align="char" char=".">0.83</td><td style="border:none;" align="left">9-octadecenal</td></tr><tr><td style="border:none;" align="left">24.</td><td style="border:none;" align="char" char=".">33.099</td><td style="border:none;" align="char" char=".">2.36</td><td style="border:none;" align="left">Stigmasterol</td></tr><tr><td style="border:none;" align="left">25.</td><td style="border:none;" align="char" char="."><bold>36.679</bold></td><td style="border:none;" align="char" char="."><bold>20.15</bold></td><td style="border:none;" align="left"><bold>Lupeol</bold></td></tr></tbody></table></table-wrap></sec><sec id="sec2.5"><label>2.5</label><title>Molecular Docking of <italic>A. nilotica</italic> Methanolic Extract of Major Constituents with the Potential Drug
Targets of <italic>L. donovani</italic></title><p>The
TR and SMT enzymes were modeled using Modeller 9.24, and the energy
minimization was carried out by BIOVIA Discovery Studio. The three-dimensional
(3D) cartoon representation of TR and SMT enzymes is shown in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.1c00366/suppl_file/ao1c00366_si_001.pdf">Figures S1A and S2A</ext-link>. The models were selected
by analyzing their stereochemical quality using the PROCHECK program.
The generated models of TR and SMT show a good quality structure having
99.8 and 99% residues in the allowed regions of the Ramachandran plot,
respectively (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.1c00366/suppl_file/ao1c00366_si_001.pdf">Figures S1B and S2B</ext-link>). The
PDBsum tool was used to analyze and found that the 3D structure of
the enzyme is composed of mixed &#x003b1;-helices and &#x003b2;-strand
(&#x003b1; + &#x003b2;) secondary structures.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> The structural topology of TR and SMT showed 5 sheets, 23 strands,
18 helices, and 34 &#x003b2; turns and 2 sheets, 10 strands, 14 helices,
and 41 &#x003b2; turns, respectively (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.1c00366/suppl_file/ao1c00366_si_001.pdf">Figures S1C,D and S2C,D</ext-link>). Multiple sequence alignments were performed, and
Discovery Studio was used to find the key residues and regions around
the binding cavity of TR and SMT. The active site residues of the
SMT, TR, PTR1, and APT enzymes making different numbers of hydrogen
bonds as well as hydrophobic bonds with the ligands were also identified.
Based on binding affinity, lupeol; 9,12-octadecadienoic acid; 6-octadecenoic
acid; and 13-docosenoic acid have binding energies of &#x02212;8.5,
&#x02212;5.7, &#x02212;5.7, and &#x02212;5.6 kcal/mol; &#x02212;8.4, &#x02212;4.9, &#x02212;4.9,
and &#x02212;4.7 kcal/mol; &#x02212;7.9, &#x02212;5.3, &#x02212;4.4, and
&#x02212;5.4 kcal/mol; and &#x02212;6.2, &#x02212;6.1, &#x02212;5.9, and&#x02013;5.9
kcal/mol with SMT, TR, PTR1, and APT enzymes, respectively (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). The binding pattern
of lupeol with SMT, TR, PTR1, and APT may hinder the substrate accessibility
and its subsequent inhibition, as shown in <xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>a, where the binding energies and inhibition
constants are &#x02212;8.5, &#x02212;8.4, &#x02212;7.9, and &#x02212;6.2
kcal/mol and 6.25, 6.12, 5.81, and 4.56 &#x003bc;M, respectively (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). It shows favorable
interactions with SMT through two &#x003c0;-alkyl bonds with Arg347
and Lys351, TR <italic>via</italic> a &#x003c0;-alkyl bond with Tyr198,
PTR1 by two &#x003c0;-alkyl bonds with Val83 and Arg88, and APRT through
a hydrogen bond with Thr151 (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>b). The binding interaction
shown by 9,12-octadecadienoic acid with SMT, TR, PTR1, and APRT may
obstruct the substrate accessibility of these proteins, which leads
to their subsequent inhibition, as shown in <xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>c, where
the binding energies and inhibition constants are &#x02212;5.7, &#x02212;4.9,
&#x02212;5.3, and &#x02212;6.1 kcal/mol and 4.19, 3.60, 3.90, and 4.49
&#x003bc;M, respectively (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). The favorable interactions are shown by 9,12-octadecadienoic
acid with SMT through a hydrogen bond with Lys198, TR <italic>via</italic> a hydrogen bond with Gly376, and PTR1 by 18 &#x003c0;-alkyl bonds
with Phe86, Lys87, Ala90, Ala94, Lys156, Ala157, His160, Arg161, and
APRT through a hydrogen bond with Arg82 (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>d). The binding
pattern of 6-octadecenoic acid with SMT, TR, PTR1, and APRT may lead
to their subsequent inhibition by obstructing their substrate accessibility,
as shown in <xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>e, where the binding energies and
inhibition constants are &#x02212;5.7, &#x02212;4.9, &#x02212;4.4, and
&#x02212;5.9 kcal/mol and 4.19, 3.60, 3.24, and 4.34 &#x003bc;M, respectively
(<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p><italic>A. nilotica</italic> major chemical constituents
inhibited SMT of <italic>L. donovani</italic><italic>in silico</italic>. (a) Lupeol blocked the binding pocket of the
SMT enzyme. (b) 2D plot showing interactions between the receptor
and ligand. (c) 9,12-Octadecadienoic acid blocked the binding pocket
of the SMT enzyme. (d) 2D plot showing interactions between the receptor
and ligand. (e) 6-Octadecenoic acid blocking the binding pocket of
the SMT enzyme. (f) 2D plot showing interactions between the receptor
and ligand. (g) 13-Docosenoic acid blocking the binding pocket of
the SMT enzyme. (h) 2D plot showing interactions between the receptor
and ligand.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0004" id="gr3" position="float"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p><italic>A. nilotica</italic> major
chemical constituents
inhibited TR of <italic>L. donovani</italic><italic>in silico</italic>. (a) Lupeol blocked the binding pocket of the
TR enzyme. (b) 2D plot showing interactions between the receptor and
ligand. (c) 9,12-Octadecadienoic acid blocked the binding pocket of
the TR enzyme. (d) 2D plot showing interactions between the receptor
and ligand. (e) 6-Octadecenoic acid blocking the binding pocket of
the TR enzyme. (f) 2D plot of 6-octadecinoic acid showing interactions
between the receptor and ligand. (g) 13-Docosenoic acid blocked the
binding pocket of the TR enzyme. (h) 2D plot showing interactions
between the receptor and ligand.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0005" id="gr4" position="float"/></fig><fig id="fig5" position="float"><label>Figure 5</label><caption><p><italic>A. nilotica</italic> major chemical constituents
inhibited PTR1 of <italic>L. donovani</italic><italic>in silico</italic>. (a) Lupeol blocked the binding pocket of the
PTR1 (PDB ID: 2XOX) enzyme. (b) 2D plot showing interactions between the receptor and
ligand. (c) 9,12-Octadecadienoic acid blocking the binding pocket
of the PTR1 (PDB ID: 2XOX) enzyme. (d) 2D plot showing interactions between the receptor and
ligand. (e) 6-Octadecenoic acid blocked the binding pocket of the
PTR1 (PDB ID: 2XOX) enzyme. (f) 2D plot showing interactions between the receptor and
ligand. (g) 13-Docosenoic acid blocked the binding pocket of the PTR1
(PDB ID: 2XOX) enzyme. (h) 2D plot showing interactions between the receptor and
ligand.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0006" id="gr5" position="float"/></fig><fig id="fig6" position="float"><label>Figure 6</label><caption><p><italic>A. nilotica</italic> major
chemical constituents
inhibited APRT of <italic>L. donovani</italic><italic>in silico</italic>. (a) Lupeol blocked the binding pocket of the
APRT (PDB ID: 1QB7) enzyme. (b) 2D plot showing interactions between the receptor and
ligand. (c) 9,12-Octadecadienoic acid blocked the binding pocket of
the APRT (PDB ID: 1QB7) enzyme. (d) 2D plot showing interactions between the receptor and
ligand. (e) 6-Octadecenoic acid blocked the binding pocket of the
APRT (PDB ID: 1QB7) enzyme. (f) 2D plot showing interactions between the receptor and
ligand. (g) 13-Docosenoic acid blocked the binding pocket of the APRT
(PDB ID: 1QB7) enzyme. (h) 2D plot showing interactions between the receptor and
ligand.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_0007" id="gr6" position="float"/></fig><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Molecular Docking
Interaction of Abundant
Medicinal Constituents of the <italic>A. nilotica</italic> Bark Methanolic Extract Shows Significant Inhibition of <italic>L. donovani</italic> Target Proteins</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">S. no.</th><th style="border:none;" align="center">Proteins</th><th style="border:none;" align="center">Ligands</th><th style="border:none;" align="center" char=".">binding
energy (kcal/mol)</th><th style="border:none;" align="center" char=".">p<italic>K</italic><sub>i,pred</sub> (&#x003bc;M)</th><th style="border:none;" align="center">interacting residues</th></tr></thead><tbody><tr><td style="border:none;" align="left">1.</td><td style="border:none;" align="left">SMT</td><td style="border:none;" align="left">Lupeol</td><td style="border:none;" align="char" char=".">&#x02013;8.5</td><td style="border:none;" align="char" char=".">6.25</td><td style="border:none;" align="left">Lys198, Tyr206, Met210,
Asn215, Pro216, Asn217, Cys240, Gln242,
Leu322, Ile344, Arg347, Lys348, Lys351</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.7</td><td style="border:none;" align="char" char=".">4.19</td><td style="border:none;" align="left"><bold>Lys198</bold>, Cys202, Phe203, Tyr206, Met210, Asn215,
Asn217, Cys240, Lys241, Phe259, Gln263, Leu322, Ile344, Arg347, Lys348,
Lys351</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">6-octadecenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.7</td><td style="border:none;" align="char" char=".">4.19</td><td style="border:none;" align="left"><bold>Lys198</bold>, Cys202, Phe203, Tyr206,
Met210, Asn215,
Asn217, Cys240, Lys241, Ala257, Phe259, Ile261, Gln263, Leu322, Ile344,
Arg347, Lys348, Lys351</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.6</td><td style="border:none;" align="char" char=".">4.12</td><td style="border:none;" align="left">Lys198, Gly200, Cys202,
Phe203, Tyr206, Met210, Asn215, Pro216,
Asn217, <bold>Lys241</bold>, Phe259, <bold>Gln263</bold>, Leu322,
Ile344, Arg347, Lys348, Lys351</td></tr><tr><td style="border:none;" align="left">2.</td><td style="border:none;" align="left">TR</td><td style="border:none;" align="left">Lupeol</td><td style="border:none;" align="char" char=".">&#x02013;8.4</td><td style="border:none;" align="char" char=".">6.12</td><td style="border:none;" align="left">Gly197, Tyr198, Phe230, Val332, Met333, Leu334,
His359, Val362,
Cys364, Gly374</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">&#x02013;4.9</td><td style="border:none;" align="char" char=".">3.60</td><td style="border:none;" align="left">Tyr198, Phe230, Val332,
Met333, Cys364, <bold>Gly376</bold></td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">6-octadecenoic acid,</td><td style="border:none;" align="char" char=".">&#x02013;4.9</td><td style="border:none;" align="char" char=".">3.60</td><td style="border:none;" align="left">Gly197, Tyr198, Gly229, Phe230, Val332, Met333, Leu334, Cys362,
Cys364, Gly374, Cys375, <bold>Gly376</bold></td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;4.7</td><td style="border:none;" align="char" char=".">3.46</td><td style="border:none;" align="left">Gly197, Tyr198, Phe230, Gly286, Val332, Met333, Leu334, Lys361,
Cys362, Cys364, Gly374, Cys375, <bold>Gly376</bold></td></tr><tr><td style="border:none;" align="left">3.</td><td style="border:none;" align="left">PTR1</td><td style="border:none;" align="left">Lupeol</td><td style="border:none;" align="char" char=".">&#x02013;7.9</td><td style="border:none;" align="char" char=".">5.81</td><td style="border:none;" align="left">His38, Gln63, Ala64, Asp65, Lys71, Ala77,
Val83, Lys87, Arg88,
Asp91</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.3</td><td style="border:none;" align="char" char=".">3.90</td><td style="border:none;" align="left">Phe86, Lys87, Ala90, Ala94, Lys156, Ala157,
His160, Arg161</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">6-octadecenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;4.4</td><td style="border:none;" align="char" char=".">3.24</td><td style="border:none;" align="left">Lys71, Ala77, Val83,
Lys87, Arg88, <bold>Leu92</bold></td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.4</td><td style="border:none;" align="char" char=".">3.97</td><td style="border:none;" align="left">Val83, Phe86, Lys87, Ala90, Ala94, Lys156, Ala157, His160,
Arg161</td></tr><tr><td style="border:none;" align="left">4.</td><td style="border:none;" align="left">adenine phosphorybosyl
transferase</td><td style="border:none;" align="left">Lupeol</td><td style="border:none;" align="char" char=".">&#x02013;6.2</td><td style="border:none;" align="char" char=".">4.56</td><td style="border:none;" align="left">Pro36, Arg37, Arg82, Lys103, Glu127, Asp146,
Ala150, <bold>Thr151</bold>, Glu152, Gly153, Thr154</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">&#x02013;6.1</td><td style="border:none;" align="char" char=".">4.49</td><td style="border:none;" align="left">Trp29, Arg37, Val39, Pro40, Arg41, Phe42, Ala43, <bold>Arg82</bold>, Val148, Ala150, Leu176, Ile178, Leu181, Asp206, Leu209</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">6-octadecenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.9</td><td style="border:none;" align="char" char=".">4.34</td><td style="border:none;" align="left"><bold>Arg37</bold>, Val39, Pro40, Arg41, Phe42, Ala43, <bold>Arg82</bold>, Val148, Ala150, Leu176, Ile178, Phe180, Leu181, Asp206</td></tr><tr><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">&#x02013;5.9</td><td style="border:none;" align="char" char=".">4.34</td><td style="border:none;" align="left"><bold>Arg37</bold>, Val39, Pro40, Arg41, Phe42, Ala43, <bold>Arg82</bold>, Val148, Ala150, Leu176, Ile178, Phe180, Leu181, Asp206,
Leu209</td></tr></tbody></table></table-wrap><p>The important
and favorable interactions shown by 6-octadecenoic
acid with SMT through two &#x003c0;-alkyl bonds with Lys198, TR <italic>via</italic> a hydrogen bond with Gly376, PTR1 by a hydrogen bond
with Leu92, and APRT through two hydrogen bonds with Arg37 and Arg82
(<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>f).</p><p>The pattern of the interaction of 13-octadecenoic
acid with SMT,
TR, PTR1, and APRT may lead to their subsequent inhibition by obstructing
their substrate accessibility, as shown in <xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>g, where
the binding energies and inhibition constants are &#x02212;5.6, &#x02212;4.7,
&#x02212;5.4, and &#x02212;5.9 kcal/mol and 4.12, 3.46, 3.97, and 4.34
&#x003bc;M, respectively (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>). It shows favorable interactions with SMT through two hydrogen
bonds with Lys241 and Gln263, TR <italic>via</italic> a hydrogen bond
with Gly376, PTR1 by 20 &#x003c0;-alkyl bonds with Val83, Phe86, Lys87,
Ala90, Ala94, Lys156, Ala157, and His160, and APRT through a hydrogen
bond with Arg37 and Ar82 (<xref rid="fig3" ref-type="fig">Figures <xref rid="fig3" ref-type="fig">3</xref></xref>&#x02013;<xref rid="fig6" ref-type="fig">6</xref>h).</p></sec><sec id="sec2.6"><label>2.6</label><title>Pharmacokinetic Studies of <italic>A. nilotica</italic> Bark Methanolic Extract Constituents</title><p>The pharmacological
studies were done for the selected ligands
against APRT, PTR1, TR, and SMT proteins for a good oral administration
established through the Lipinski rule of five,<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> which was evaluated by Molsoft L.L.C.: drug-likeness and
molecular property prediction. Lipinski&#x02019;s &#x0201c;rule of five&#x0201d;
is an analytical approach for predicting drug-likeness stating that
molecules had molecular weight (MW &#x02264; 500 Da), high lipophilicity
expressed as log <italic>P</italic> (log <italic>P</italic> &#x02264;
5), hydrogen bond donors (HBDs &#x02264; 5), and hydrogen bond acceptors
(HBAs &#x02264; 10) with good absorption or permeation across the cell
membrane. Lupeol, 9,12-octadecadienoic acid, 6-octadecenoic acid,
and 13-docosenoic acid followed all the parameters of the Lipinski
rule of five, except low lipophilicity, as observed in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>. As per the Lipinski rule of
five, violation of one parameter is acceptable for an orally active
drug. The absorption percentage (AB %) was calculated using the formula.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup><disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_m001" position="anchor"/></disp-formula></p><p>It is important to
look into the pharmacokinetic
properties of the compounds, before animal and clinical studies. To
evaluate the biochemical behavior of these compounds inside an organism
in respect of absorption, distribution, metabolism, and excretion
(ADME), the SwissADME database<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> was used
to explore the drug-likeness and pharmacokinetic properties of these
compounds. The lipophilicity of lupeol, 9,12-octadecadienoic acid,
6-octadecenoic acid, and 13-docosenoic acid showed log <italic>P</italic><sub>o/w</sub> values of 4.76, 4.61, 4.73, and 5.65, respectively,
which indicates high sublingual absorption. Lupeol and 13-docosenoic
acid possess low gastrointestinal absorption and poor water-soluble
capability, whereas 9,12-octadecadienoic acid and 6-octadecenoic acid
show high gastrointestinal absorption as well as moderate water-soluble
capability. None of the compounds are permeable to the blood&#x02013;brain
barrier. 9,12-Octadecadienoic acid, 6-octadecenoic acid, and 13-docosenoic
acid are CYP1A2 inhibitors, which are likely to increase the half-life
of these compounds and also prevent serious drug interactions. The
drug-likeness criteria are qualified by all the ligands with one violation
and possess a significant bioavailability score. The results are summarized
in <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>.</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Evaluation of Physico-Chemical and
ADMET Properties Shows Feasibility of Usage of the Chemical Constituents
for the Treatment of Disease</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">ligands</th><th style="border:none;" align="center" char=".">MW (&#x0003c;500)</th><th style="border:none;" align="center" char=".">HBD (&#x0003c;5)</th><th style="border:none;" align="center" char=".">HBA (&#x0003c;10)</th><th style="border:none;" align="center" char=".">log <italic>P</italic><sub>o/w</sub> (lipophilicity)</th><th style="border:none;" align="center" char=".">TPSA (&#x02264;140)</th><th style="border:none;" align="center" char=".">absorption percentage (AB&#x000a0;%) (&#x0003e;50%)</th><th style="border:none;" align="center">drug-likeness (Lipinski violations)</th><th style="border:none;" align="center">GI-absorption</th><th style="border:none;" align="center">BBB permeant</th><th style="border:none;" align="center">CYP1A2
inhibitor</th><th style="border:none;" align="center" char=".">bioavailability score</th><th style="border:none;" align="center">water solubility (log&#x000a0;<italic>S</italic>)</th></tr></thead><tbody><tr><td style="border:none;" align="left">lupeol</td><td style="border:none;" align="char" char=".">426.39</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">1</td><td style="border:none;" align="char" char=".">4.76</td><td style="border:none;" align="char" char=".">20.23</td><td style="border:none;" align="char" char=".">102.02</td><td style="border:none;" align="left">yes; 1&#x000a0;violation</td><td style="border:none;" align="left">low</td><td style="border:none;" align="left">no</td><td style="border:none;" align="left">no</td><td style="border:none;" align="char" char=".">0.55</td><td style="border:none;" align="left">&#x02013;8.64
(poorly soluble)</td></tr><tr><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">294.48</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">4.61</td><td style="border:none;" align="char" char=".">26.30</td><td style="border:none;" align="char" char=".">99.93</td><td style="border:none;" align="left">yes; 1&#x000a0;violation</td><td style="border:none;" align="left">high</td><td style="border:none;" align="left">no</td><td style="border:none;" align="left">yes</td><td style="border:none;" align="char" char=".">0.55</td><td style="border:none;" align="left">&#x02013;4.97
(moderately soluble)</td></tr><tr><td style="border:none;" align="left">6-octadecenoic acid</td><td style="border:none;" align="char" char=".">296.50</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">4.73</td><td style="border:none;" align="char" char=".">26.30</td><td style="border:none;" align="char" char=".">99.93</td><td style="border:none;" align="left">yes; 1&#x000a0;violation</td><td style="border:none;" align="left">high</td><td style="border:none;" align="left">no</td><td style="border:none;" align="left">yes</td><td style="border:none;" align="char" char=".">0.55</td><td style="border:none;" align="left">&#x02013;5.13
(moderately soluble)</td></tr><tr><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">352.60</td><td style="border:none;" align="char" char=".">0</td><td style="border:none;" align="char" char=".">2</td><td style="border:none;" align="char" char=".">5.65</td><td style="border:none;" align="char" char=".">26.30</td><td style="border:none;" align="char" char=".">99.93</td><td style="border:none;" align="left">yes; 1&#x000a0;violation</td><td style="border:none;" align="left">low</td><td style="border:none;" align="left">no</td><td style="border:none;" align="left">yes</td><td style="border:none;" align="char" char=".">0.55</td><td style="border:none;" align="left">&#x02013;6.58
(poorly soluble)</td></tr></tbody></table></table-wrap><p>The bioactivity prediction of the major constituents of <italic>A. nilotica</italic> bark methanolic extract was analyzed
through Molinspiration. The activity was calculated against a G-protein-coupled
receptor&#x02013;ligand, an ion channel modulator, a kinase inhibitor,
a nuclear receptor ligand, a protease inhibitor, and an enzyme inhibitor.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> The interpreted values for bioactivity were
as follows: active (bioactivity score &#x02265; 0), moderately active
(bioactivity score: between &#x02212;5.0 and 0.0), and inactive (bioactivity
score &#x02264; &#x02212;5.0).<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> Lupeol,
9,12-octadecadienoic acid, 6-octadecenoic acid, and 13-docosenoic
acid were evaluated as active enzyme inhibitors with values 0.52,
0.23, 0.12, and 0.10, respectively. Lupeol and 9,12-octadecadienoic
acid were evaluated as active protease inhibitors as well as ion channel
modulators (<xref rid="tbl4" ref-type="other">Table <xref rid="tbl4" ref-type="other">4</xref></xref>).</p><table-wrap id="tbl4" position="float"><label>Table 4</label><caption><title>Bioactivity Prediction of the Selected
Ligands against <italic>L. donovani</italic> by Molinspiration</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/></colgroup><thead><tr><th style="border:none;" align="center">ligands</th><th style="border:none;" align="center" char=".">GPCR ligand</th><th style="border:none;" align="center" char=".">ion channel modulator</th><th style="border:none;" align="center" char=".">kinase inhibitor</th><th style="border:none;" align="center" char=".">nuclear receptor ligand</th><th style="border:none;" align="center" char=".">protease Inhibitor</th><th style="border:none;" align="center" char=".">enzyme inhibitor</th></tr></thead><tbody><tr><td style="border:none;" align="left">lupeol</td><td style="border:none;" align="char" char=".">0.27</td><td style="border:none;" align="char" char=".">0.11</td><td style="border:none;" align="char" char=".">&#x02013;0.42</td><td style="border:none;" align="char" char=".">0.85</td><td style="border:none;" align="char" char=".">0.15</td><td style="border:none;" align="char" char=".">0.52</td></tr><tr><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">0.15</td><td style="border:none;" align="char" char=".">0.07</td><td style="border:none;" align="char" char=".">&#x02013;0.20</td><td style="border:none;" align="char" char=".">0.14</td><td style="border:none;" align="char" char=".">0.03</td><td style="border:none;" align="char" char=".">0.23</td></tr><tr><td style="border:none;" align="left">6-octadecenoic acid</td><td style="border:none;" align="char" char=".">0.03</td><td style="border:none;" align="char" char=".">&#x02013;0.03</td><td style="border:none;" align="char" char=".">&#x02013;0.25</td><td style="border:none;" align="char" char=".">0.06</td><td style="border:none;" align="char" char=".">&#x02013;0.02</td><td style="border:none;" align="char" char=".">0.12</td></tr><tr><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">0.07</td><td style="border:none;" align="char" char=".">&#x02013;0.02</td><td style="border:none;" align="char" char=".">&#x02013;0.17</td><td style="border:none;" align="char" char=".">0.10</td><td style="border:none;" align="char" char=".">0.07</td><td style="border:none;" align="char" char=".">0.10</td></tr></tbody></table></table-wrap><p>The principal aim of predicting acute
toxicity is to evaluate undesirable
side effects of a compound after single or multiple exposures to an
organism <italic>via</italic> a known administration route (oral,
inhalation, subcutaneous, intravenous, or intraperitoneal). GUSAR
was used to determine the acute toxicity of the successfully docked
compounds. The parameters used by GUSAR to probe compounds are based
on the prediction of activity spectra for substance algorithm and
quantitative neighborhoods of atom descriptors. The obtained results
were compared with the SYMYX MDL Toxicity Database to further categorize
them based on the Organisation for Economic Co-operation and Development
(OECD) chemical classification manual.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> The criteria used for these compounds to elicit toxicity are based
upon the administration route when the compound dose is more than
7000 mg/kg for an intravenous route, more than 500,000 mg/kg in case
of the oral route, and more than 20,000 mg/kg for the intraperitoneal
route and subcutaneous database, as shown in <xref rid="tbl5" ref-type="other">Table <xref rid="tbl5" ref-type="other">5</xref></xref>.</p><table-wrap id="tbl5" position="float"><label>Table 5</label><caption><title>Acute Toxicity Shows
the Lethal Dose
and Extent of Toxicity of Chemical Constituents on Rodent Models<xref rid="t5fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">S. no.</th><th style="border:none;" align="center">Ligands</th><th style="border:none;" align="center" char=".">rat oral LD<sub>50</sub> (mg/kg)</th><th style="border:none;" align="center" char=".">rat IV LD<sub>50</sub> (mg/kg)</th><th style="border:none;" align="center" char=".">rat SC LD<sub>50</sub> (mg/kg)</th><th style="border:none;" align="center" char=".">rat IP LD<sub>50</sub> (mg/kg)</th><th style="border:none;" align="center">OECD chemical classification</th></tr></thead><tbody><tr><td style="border:none;" align="left">1.</td><td style="border:none;" align="left">Lupeol</td><td style="border:none;" align="char" char=".">2,888,000</td><td style="border:none;" align="char" char=".">5867</td><td style="border:none;" align="char" char=".">786,900</td><td style="border:none;" align="char" char=".">1,684,000</td><td style="border:none;" align="left">class&#x000a0;5</td></tr><tr><td style="border:none;" align="left">2.</td><td style="border:none;" align="left">9,12-octadecadienoic acid</td><td style="border:none;" align="char" char=".">8,747,000</td><td style="border:none;" align="char" char=".">309,300</td><td style="border:none;" align="char" char=".">9,261,000</td><td style="border:none;" align="char" char=".">4,673,000</td><td style="border:none;" align="left">non-toxic</td></tr><tr><td style="border:none;" align="left">3.</td><td style="border:none;" align="left">6-octadecenoic acid</td><td style="border:none;" align="char" char=".">7,813,000</td><td style="border:none;" align="char" char=".">381,700</td><td style="border:none;" align="char" char=".">7,007,000</td><td style="border:none;" align="char" char=".">3,028,000</td><td style="border:none;" align="left">non-toxic</td></tr><tr><td style="border:none;" align="left">4.</td><td style="border:none;" align="left">13-docosenoic acid</td><td style="border:none;" align="char" char=".">9,279,000</td><td style="border:none;" align="char" char=".">428,600</td><td style="border:none;" align="char" char=".">11,160,000</td><td style="border:none;" align="char" char=".">5,206,000</td><td style="border:none;" align="left">non-toxic</td></tr></tbody></table><table-wrap-foot><fn id="t5fn1"><label>a</label><p>As per the OECD chemical classification,
9,12-octadecadienoic acid, 6-octadecenoic acid, and 13-docosenoic
acid are found to be nontoxic and lupeol is a class 5 chemical.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec3"><label>3</label><title>Discussion</title><p>Plant extracts have promising medicinal properties and are extensively
used in the traditional system of medicine due to the presence of
many active phytoconstituents.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> From the
previous studies, it has been revealed that many medicinal plant extracts
and their secondary metabolite contents have proven to be efficient
and low-toxic antileishmanial drug candidates.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup><italic>A. nilotica,</italic> which has been identified
as potential medicinal plants, is rich in secondary metabolites. Studies
based on the GC&#x02013;MS analysis of <italic>A. nilotica</italic> showed the presence of different types of secondary plant metabolites
including polyphenols, mainly composed of condensed tannin and phlobatannin
in addition to gallic acid, ellagic acid, catechin, epigallocatechin-7-gallate,
flavonoids, and gum.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Different solvent
extracts of <italic>A. nilotica</italic> had been shown
to have antimicrobial activities including antibacterial, antifungal,
antiviral, and antiamoebic.<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> We evaluated the antileishmanial potential of <italic>A.
nilotica</italic> and identified its secondary metabolite constituents
by GC&#x02013;MS analysis. <italic>A. nilotica</italic> bark methanolic extract inhibited the growth of <italic>L.
donovani</italic> promastigotes in a time and dose-dependent
manner. It induced morphological changes and a cytocidal mode of parasite
killing. The cytocidal mode of the killing of <italic>A. nilotica</italic> maybe because of its richness in phenolic compounds,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> which may cause irreversible changes to the
cell membrane.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> Methanolic extract of
the fruit of <italic>A. nilotica</italic> had been reported
to have antileishmanial activity with an IC<sub>50</sub> value of
89.38 &#x003bc;g/mL on the <italic>Leishmania major</italic> promastigotes.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> We determined the IC<sub>50</sub> value of <italic>A. nilotica</italic> on <italic>L. donovani</italic> as 19.6 &#x000b1; 0.9037 &#x003bc;g/mL, which
was higher in comparison to the IC<sub>50</sub> value of positive
control miltefosine (3.118 &#x000b1; 0.2395 &#x003bc;g/mL). However, the
CC<sub>50</sub> value of <italic>A. nilotica</italic> on macrophages was determined as 432.7 &#x000b1; 7.71 &#x003bc;g/mL,
while that of the miltefosine was 8.219 &#x000b1; 0.6337 &#x003bc;g/mL.
The plant extract significantly inhibited the growth of the intramacrophagic
form of the parasites. The IC<sub>50</sub> value of the extract on
the amastigote form was calculated as 77.52 &#x000b1; 5.167 &#x003bc;g/mL. <italic>A. nilotica</italic> was found to have low cytotoxicity even
after having a higher IC<sub>50</sub> value as compared to the miltefosine.
Therefore, the higher concentration of <italic>A. nilotica</italic> can be used to inhibit the growth of amastigotes inside macrophages.
The major constituents identified through GC&#x02013;MS analysis were
13-docosenoic acid (34.06%), lupeol (20.15%), 9,12-octadecadienoic
acid (9.92%), and 6-octadecanoic acid (8.43%). To dissect the mechanism
of antileishmanial activity of <italic>A. nilotica</italic>, we further performed the molecular docking study of major constituents
of extract identified by GC&#x02013;MS, with essential enzymes of <italic>Leishmania</italic> including SMT, TR, PTR1, and APRT. These
enzymes play an essential role in parasite growth, survival, virulence,
and transmission inside the host. SMT is required for the biosynthesis
of ergosterol, the major membrane sterol in <italic>L. donovani</italic>.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> The enzyme TR followed the thiol-redox
metabolism to keep trypanothione in a reduced form. This antioxidant
property of TR is essential for the survival of <italic>L.
donovani</italic>.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> PTR1 catalyzed
the reduction of conjugated and nonconjugated pterins such as reduced
biopterin to dihydrobiopterin.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> APRT plays
a vital role in the purine metabolism by converting 6-aminopurines
into 6-oxypurines.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> Molecular docking
results proved that lupeol and 9,12-octadecadienoic acid possessed
higher binding affinity with SMT, TR, PTR1, and APRT, as shown in <xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>. Pharmacological
studies of these selected inhibitors for the Lipinski rule of 5 indicated
the violation of only one Lipinski parameter, as shown in <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>. The pharmacokinetic
properties and acute toxicity of lupeol; 9,12-octadecadienoic acid;
6-octadecenoic acid; and 13-docosenoic acid showed a relatively low
toxicity profile, which meant the requirement of higher doses to evoke
a toxic response. The majority of the compounds were identified as
nontoxic chemicals, whereas lupeol was a class 5 chemical with very
low toxic effects.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> The pharmacokinetic
attributes were in favor of these compounds to be exploited as promising
antileishmanial drug candidates. The earlier studies had reported
that at low concentrations, the ethyl-acetate extract of <italic>A. nilotica</italic> husk induced an increased number of human
lymphocyte cell count. This property of the extract may be considered
as a human immunity booster.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Thus, <italic>in vitro</italic>, molecular docking, pharmacokinetic studies, bioactivity
scores, and acute toxicity studies suggested possible inhibitory mechanisms
of antileishmanial activity of the extract by inhibiting the key enzymes
of <italic>Leishmania</italic>.</p></sec><sec id="sec4"><label>4</label><title>Materials
and Methods</title><sec id="sec4.1"><label>4.1</label><title>Chemicals</title><p>M199 media, Roswell Park
Memorial Institute (RPMI) 1640 media, penicillin&#x02013;streptomycin
antibiotic cocktail, and fetal bovine serum (FBS) were purchased from
Gibco. <italic>N</italic>-2-Hydroxyethylpiperazine-<italic>N</italic>&#x02032;-2-ethanesulfonic acid , sodium bicarbonate, and paraformaldehyde
were purchased from Sigma-Aldrich, Saint Louis, MO, USA. Miltefosine,
MTT assay reagents, DMSO, and different solvents were procured from
Merck &#x00026; Co., Inc., Kenilworth, NJ, USA. Propidium iodide and the
annexin V apoptosis kit were procured from Thermo Scientific. All
the other chemicals and reagents were purchased from Sigma-Aldrich,
Saint Louis, MO, USA or Merck &#x00026; Co., Inc., Kenilworth, NJ, USA.
unless stated otherwise.</p></sec><sec id="sec4.2"><label>4.2</label><title>Parasites and Cell Culture</title><p>The infective
strain of <italic>L. donovani</italic> (MHOM/IN/83/AG83)
was obtained from Dr. Rentala Madhubala (School of Life Science JNU,
New Delhi, India). THP-1, a human monocytic cell line, was procured
from the Cell Repository of National Centre for Cell Science, Pune,
India. It was further maintained in M199 media. Human monocytic cell
line, THP-1, was maintained in RPMI 1640 media supplemented with 10%
FBS and 1% penicillin&#x02013;streptomycin antibiotic medium in a humidified
environment at 5% CO<sub>2</sub> and 37 &#x000b0;C temperature. The THP-1
monocytic cell was differentiated to macrophages by using phorbol
myristate acetate at a concentration of 20 ng/mL.</p></sec><sec id="sec4.3"><label>4.3</label><title>Extract Preparation and Antileishmanial Activity</title><p><italic>A. nilotica</italic> was collected from natural
habitats. Bark identification was done at the National Institute of
Science Communication and Information Resources (NISCAIR), New Delhi,
India. The selected plant material was washed and air-dried in shade
at room temperature. The powdered plant materials were soaked in methanol
and placed on a rotary shaker at room temperature for 24 h. The extract
was filtered and concentrated using a rotatory evaporator under vacuum
at 35 &#x000b0;C. The dried plant extract was stored at &#x02212;20 &#x000b0;C
until used for bioassay. To evaluate the antipromastigote potential
of <italic>A. nilotica</italic>, stationary phase (2
&#x000d7; 10<sup>6</sup> cells/mL) promastigotes were incubated with
plant extract for 48 h, followed by fixing using 1% paraformaldehyde
and counting through a hemocytometer at 22 &#x000b0;C. Miltefosine, a
known antileishmanial drug, was used as the positive control. Percent
viability was determined using the formula<disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_m002" position="anchor"/></disp-formula>50% inhibitory concentration
(IC<sub>50</sub>) at which parasite growth was reduced by 50% and
was assessed by
GraphPad Prism 7.00, nonlinear regression curve fit.</p></sec><sec id="sec4.4"><label>4.4</label><title>Cytotoxicity Assessment and Antiamastigote
Evaluation of Extract</title><p>The cytotoxicity of <italic>A. nilotica</italic> on THP-1-differentiated macrophages was
assessed by MTT. Briefly, 2 &#x000d7; 10<sup>6</sup> THP-1 monocytes
were seeded in a 96-well tissue culture plate (200 &#x003bc;L/well)
in RPMI 1640 complete media for 24 h in an Eppendorf Galaxy 170S CO<sub>2</sub> incubator (Eppendorf India Pvt. Ltd.) at 37 &#x000b0;C and 5%
CO<sub>2</sub>. After the treatment of THP-1-differentiated macrophages,
freshly prepared 5 mg/mL of MTT was added (20 &#x003bc;L/well) with
50 &#x003bc;L of blank media and further incubated for 2&#x02013;3 h
in a CO<sub>2</sub> incubator. Precipitated formazan was dissolved
in DMSO; absorbance was recorded at 570 nm in an enzyme-linked immunosorbent
assay plate reader and percent viability was calculated as per the
lab&#x02019;s established and published protocol.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> To determine the effect of <italic>A. nilotica</italic> on the parasite burden of the host macrophages, 0.5 &#x000d7; 10<sup>6</sup> THP-1 cells were seeded on the coverslip and placed in the
six-well plates in a CO<sub>2</sub> incubator at 37 &#x000b0;C. THP-1
macrophages were plated and infected with <italic>L. donovani</italic> at the ratio of 1:10 (macrophages to <italic>Leishmania</italic>) for 48 h. Then, cells were fixed with chilled methanol and parasite
counting was performed under the microscope after Giemsa staining.
From the different focus, 100 macrophages were counted to determine
the parasite burden of the macrophages. Parasite burden in the infection
control was considered 100%, with respect to the parasite load in
treated samples.</p></sec><sec id="sec4.5"><label>4.5</label><title>GC&#x02013;MS Analysis of
Extract</title><p>GC&#x02013;MS analysis was performed to identify the
secondary metabolites
that may be responsible for the antileishmanial efficacy of <italic>A. nilotica</italic>. Bark was crushed, powdered, and extracted
in methanol and then analyzed on Shimadzu QP2010; GCMS-QP2010 SE:
SHIMADZU (Shimadzu Corporation) armed with a DB-5MS column at AIRF,
Jawaharlal University, New Delhi, India, as per the established methodology.
The mass spectra of the sample were produced in an electron impact
ionization mode of 70 eV, and the phytochemicals were identified after
the correlation of the recorded mass spectrum with the reference library
WILEY8.LIB and NIST14.LIB supplied with the software of the GC&#x02013;MS
system.</p></sec><sec id="sec4.6"><label>4.6</label><title>Molecular Docking Studies</title><p>To begin
with structure-based virtual screening and docking, we used various
bioinformatics tools, such as PyRx,<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> AutoDock
Vina,<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> PyMOL,<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> and BIOVIA Discovery Studio 2020 pipeline.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> The online resources used in the retrieval, analysis, and evaluation
of the data are the PubChem database and RCSB Protein Data Bank (PDB).<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> The target proteins of <italic>L. donovani</italic> and the phytochemical compounds were uploaded into the virtual screening
program PyRx. The target protein was changed into a macromolecule,
which converted the atomic coordinates into a pdbqt format. Molecular
docking was performed by selecting the grid box around the crystal
structures, and the rest of the parameters were left as default. AutoDock
Vina was used to predict the binding mode and the best binding affinity
of the phytochemicals. The algorithm used by AutoDock Vina is a hybrid
scoring function that is inspired by <italic>X</italic>-score, which
accounts for hydrogen bonding, hydrophobic effect, van der Waals forces,
and deformation penalty. Besides, for computing, the binding energy
AutoDock Vina combines both the conformational preferences of the
receptor&#x02013;ligand complex and experimental affinity measurements.
The results of molecular docking were screened for binding affinity,
and then, all possible docked conformations were generated for different
constituents. After analyzing with PyMOL and Discovery Studio, only
those conformations were selected which specifically interact with
the active-site residues of <italic>L. donovani</italic>-targeted proteins. Discovery Studio was used to analyze detailed
interactions and their types including hydrogen bonds, alkyl, &#x003c0;-alkyl,
halogen, and the van der Waals interactions formed between different
constituents and the target proteins. The most favorable binding poses
of the rutin were analyzed by choosing the lowest free energy of binding
(&#x00394;<italic>G</italic>) and the lowest inhibition constant (<italic>K</italic><sub>i</sub>) which is calculated using the following formula<disp-formula id="ueq3"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_m003" position="anchor"/></disp-formula>where &#x00394;<italic>G</italic> is
the binding
affinity (kcal/mol), <italic>R</italic> (gas constant) is 1.98 cal
K<sup>&#x02013;1</sup> mol<sup>&#x02013;1</sup>, and <italic>T</italic> (room temperature) is 298.15 K.</p></sec><sec id="sec4.7"><label>4.7</label><title>Sequence
Analysis, Template Identification,
Homology Modeling, and Receptor and Ligand Preparation</title><p>The
protein sequences of TR (XP_003858222.1) and SMT (XP_003865366.1)
from <italic>L. donovani</italic> were retrieved from
NCBI. The blastP<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> was performed against
Protein Data Bank for the identification of similar templates. The
alignment of the query sequences and template sequences was performed
using CLUSTAL &#x003a9;.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> The crystal structure
of TR from <italic>Leishmania infantum</italic> 2.95
&#x000c5; resolution (PDB id: 2JK6_A) and X-ray diffracted crystal structure 1.34 &#x000c5;
resolution (PDB id: 5WP4_A) were used as template structures to model the 3D structures of
TR and SMT, respectively. PDB was used to retrieve the template structure.
Homology modeling was carried out using Modeller 9.24,<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> and PyMol was used for the visualization of
the 3D structures. The energy minimization was performed using Discovery
Studio. The PROCHECK program and Ramachandran plots were also used
for the assessment of the model.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p><p>Crystal structures of the APRT and PTR1 proteins were downloaded
from PDB [IDs: 1QB7 (APRT) and 2XOX (PTR1)]. The PDB files used for the docking-based virtual screening
study were processed by removing water molecules and adding hydrogen
atoms. The proteins were finally prepared by Discovery Studio keeping
all the parameters at default. The identification of the critical
residues of the binding pockets was taken from the native binding
pockets of the available crystal structure of proteins, various submitted
literature studies, from their homologous template proteins, and investigation
in the mechanism of inhibition. The 3D structure of 9,12-octadecadienoic
acid, 6-octadecenoic acid, 13-docosenoic acid, and lupeol was retrieved
from the PubChem database in an SDF format. The atomic coordinates
of all the ligands were changed to a pdbqt setup using Open Babel
GUI, an open-source chemical toolbox for the interconversion of chemical
structures.<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> Universal force field was
used for the energy minimization.<sup><xref ref-type="bibr" rid="ref53">53</xref></sup></p></sec><sec id="sec4.8"><label>4.8</label><title>Pharmacokinetic Studies</title><p>The selected
ligands were evaluated for their pharmacological profiles by analyzing
for Lipinski&#x02019;s rule of 5, which was analyzed by Molsoft L.L.C.:
drug-likeness and molecular property prediction for drug-likeness
(<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.molsoft.com/mprop/">http://www.molsoft.com/mprop/</uri>). The bioactivity of the selected inhibitors was checked by Molinspiration
(<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://molinspiration.com/cgi-bin/properties">https://molinspiration.com/cgi-bin/properties</uri>). The successfully screened ligands were further evaluated for ADMET
(absorption, distribution, metabolism, excretion, and toxicity) properties
by GUSAR<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> and the SwissADME database.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup></p></sec></sec></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.1c00366?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.1c00366</ext-link>.<list id="silist" list-type="simple"><list-item><p>Homology-modeled TR and
SMT structures validated through
the Ramachandran plot (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acsomega.1c00366/suppl_file/ao1c00366_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao1c00366_si_001.pdf"><caption><p>ao1c00366_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes3"><title>Author Contributions</title><p><sup>&#x000b6;</sup> R.A., S.T., and F.R. contributed equally.</p></notes><notes notes-type="funding-statement" id="notes2"><p>The authors would
like to thank the Deanship of Scientific Research at Majmaah University,
Al Majmaah, 11952, Saudi Arabia, for supporting this work under the
Group Project Number RGP-2019-31. The authors are also thankful to
the Ministry of Ayush for funding [Z.28015/252/2016-HPC (EMR)-AYUSH-C].</p></notes><notes notes-type="COI-statement" id="NOTES-d7e2441-autogenerated"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>R.A. is thankful to the Ministry of Ayush, GoI for
Senior Research Fellowship.</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Oryan</surname><given-names>A.</given-names></name>; <name><surname>Akbari</surname><given-names>M.</given-names></name>
<article-title>Worldwide risk factors
in leishmaniasis</article-title>. <source>Asian Pac. J. Trop. Med.</source>
<year>2016</year>, <volume>9</volume>, <fpage>925</fpage>&#x02013;<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1016/j.apjtm.2016.06.021</pub-id>.<pub-id pub-id-type="pmid">27794384</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Murray</surname><given-names>H. W.</given-names></name>; <name><surname>Berman</surname><given-names>J. D.</given-names></name>; <name><surname>Davies</surname><given-names>C. R.</given-names></name>; <name><surname>Saravia</surname><given-names>N. G.</given-names></name>
<article-title>Advances in leishmaniasis</article-title>. <source>Lancet</source>
<year>2005</year>, <volume>366</volume>, <fpage>1561</fpage>&#x02013;<lpage>1577</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(05)67629-5</pub-id>.<pub-id pub-id-type="pmid">16257344</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Mamun
Huda</surname><given-names>M.</given-names></name>; <name><surname>Hirve</surname><given-names>S.</given-names></name>; <name><surname>Siddiqui</surname><given-names>N. A.</given-names></name>; <name><surname>Malaviya</surname><given-names>P.</given-names></name>; <name><surname>Banjara</surname><given-names>M. R.</given-names></name>; <name><surname>Das</surname><given-names>P.</given-names></name>; <name><surname>Kansal</surname><given-names>S.</given-names></name>; <name><surname>Gurung</surname><given-names>C. K.</given-names></name>; <name><surname>Naznin</surname><given-names>E.</given-names></name>; <name><surname>Rijal</surname><given-names>S.</given-names></name>
<article-title>Active case
detection in national visceral leishmaniasis elimination programs
in Bangladesh, India, and Nepal: feasibility, performance and costs</article-title>. <source>BMC Public Health</source>
<year>2012</year>, <volume>12</volume>, <fpage>1001</fpage><pub-id pub-id-type="doi">10.1186/1471-2458-12-1001</pub-id>.<pub-id pub-id-type="pmid">23164318</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Piscopo</surname><given-names>T. V.</given-names></name>; <name><surname>Mallia Azzopardi</surname><given-names>C.</given-names></name>
<article-title>Leishmaniasis</article-title>. <source>Postgrad. Med.
J.</source>
<year>2007</year>, <volume>83</volume>, <fpage>649</fpage>&#x02013;<lpage>657</lpage>. <pub-id pub-id-type="doi">10.1136/pgmj.2006.047340corr1</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Ahmad
Kiadaliri</surname><given-names>A.</given-names></name>
<article-title>Global, regional, and national disability-adjusted
life-years (DALYs) for 315 diseases and injuries and healthy life
expectancy (HALE), 1990-2015: a systematic analysis for the Global
Burden of Disease Study 2015</article-title>. <source>Lancet</source>
<year>2016</year>, <volume>388</volume>, <fpage>1603</fpage>&#x02013;<lpage>1658</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)31460-X</pub-id>.<pub-id pub-id-type="pmid">27733283</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Naghavi</surname><given-names>M.</given-names></name>; <name><surname>Allen</surname><given-names>C.</given-names></name>; <name><surname>Barber</surname><given-names>R. M.</given-names></name>; <name><surname>Bhutta</surname><given-names>Z. A.</given-names></name>; <name><surname>Carter</surname><given-names>A.</given-names></name>; <name><surname>Casey</surname><given-names>D. C.</given-names></name>; <name><surname>Charlson</surname><given-names>F. J.</given-names></name>; <name><surname>Chen</surname><given-names>A. Z.</given-names></name>; <name><surname>Coates</surname><given-names>M. M.</given-names></name>
<article-title>Global, regional,
and national life expectancy, all-cause
mortality, and cause-specific mortality for 249 causes of death, 1980&#x02013;2015:
a systematic analysis for the Global Burden of Disease Study 2015</article-title>. <source>Lancet</source>
<year>2016</year>, <volume>388</volume>, <fpage>1459</fpage>&#x02013;<lpage>1544</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)31012-1</pub-id>.<pub-id pub-id-type="pmid">27733281</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Desjeux</surname><given-names>P.</given-names></name>
<article-title>The increase
in risk factors for leishmaniasis worldwide</article-title>. <source>Trans. R. Soc. Trop. Med. Hyg.</source>
<year>2001</year>, <volume>95</volume>, <fpage>239</fpage>&#x02013;<lpage>243</lpage>. <pub-id pub-id-type="doi">10.1016/s0035-9203(01)90223-8</pub-id>.<pub-id pub-id-type="pmid">11490989</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Sundar</surname><given-names>S.</given-names></name>
<article-title>Drug resistance
in Indian visceral leishmaniasis</article-title>. <source>Trop. Med.
Int. Health</source>
<year>2001</year>, <volume>6</volume>, <fpage>849</fpage>&#x02013;<lpage>854</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-3156.2001.00778.x</pub-id>.<pub-id pub-id-type="pmid">11703838</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Chouhan</surname><given-names>G.</given-names></name>; <name><surname>Islamuddin</surname><given-names>M.</given-names></name>; <name><surname>Want</surname><given-names>M. Y.</given-names></name>; <name><surname>Abdin</surname><given-names>M. Z.</given-names></name>; <name><surname>Ozbak</surname><given-names>H. A.</given-names></name>; <name><surname>Hemeg</surname><given-names>H. A.</given-names></name>; <name><surname>Sahal</surname><given-names>D.</given-names></name>; <name><surname>Afrin</surname><given-names>F.</given-names></name>
<article-title>Apoptosis mediated
leishmanicidal activity of Azadirachta indica bioactive fractions
is accompanied by Th1 immunostimulatory potential and therapeutic
cure in vivo</article-title>. <source>Parasites Vectors</source>
<year>2015</year>, <volume>8</volume>, <fpage>183</fpage><pub-id pub-id-type="doi">10.1186/s13071-015-0788-3</pub-id>.<pub-id pub-id-type="pmid">25884649</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Islamuddin</surname><given-names>M.</given-names></name>; <name><surname>Chouhan</surname><given-names>G.</given-names></name>; <name><surname>Tyagi</surname><given-names>M.</given-names></name>; <name><surname>Abdin</surname><given-names>M. Z.</given-names></name>; <name><surname>Sahal</surname><given-names>D.</given-names></name>; <name><surname>Afrin</surname><given-names>F.</given-names></name>
<article-title>Leishmanicidal activities of Artemisia
annua leaf essential oil against
Visceral Leishmaniasis</article-title>. <source>Front. Microbiol.</source>
<year>2014</year>, <volume>5</volume>, <fpage>626</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2014.00626</pub-id>.<pub-id pub-id-type="pmid">25505453</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Hill</surname><given-names>A. F.</given-names></name>
<article-title>Some nomenclatorial
problems in Acacia</article-title>. <source>Bot. Mus. Leafl., Harv.
Univ.</source>
<year>1940</year>, <volume>8</volume>, <fpage>93</fpage>&#x02013;<lpage>105</lpage>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Bargali</surname><given-names>K.</given-names></name>; <name><surname>Bargali</surname><given-names>S.</given-names></name>
<article-title>Acacia nilotica: a
multipurpose leguminous plant</article-title>. <source>Nat. Sci.</source>
<year>2009</year>, <volume>7</volume>, <fpage>11</fpage>&#x02013;<lpage>19</lpage>.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Leela</surname><given-names>V.</given-names></name>; <name><surname>Kokila</surname><given-names>L.</given-names></name>; <name><surname>Lavanya</surname><given-names>R.</given-names></name>; <name><surname>Saraswathy</surname><given-names>A.</given-names></name>; <name><surname>Brindha</surname><given-names>P.</given-names></name>
<article-title>Determination of gallic acid in Acacia
nilotica Linn.
by HPTLC</article-title>. <source>Int. J. Pharm. Technol.</source>
<year>2010</year>, <volume>2</volume>, <fpage>285</fpage>&#x02013;<lpage>292</lpage>.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Singh</surname><given-names>B. N.</given-names></name>; <name><surname>Singh</surname><given-names>B. R.</given-names></name>; <name><surname>Singh</surname><given-names>R. L.</given-names></name>; <name><surname>Prakash</surname><given-names>D.</given-names></name>; <name><surname>Sarma</surname><given-names>B. K.</given-names></name>; <name><surname>Singh</surname><given-names>H. B.</given-names></name>
<article-title>Antioxidant and
anti-quorum sensing activities of green
pod of Acacia nilotica L</article-title>. <source>Food Chem. Toxicol.</source>
<year>2009</year>, <volume>47</volume>, <fpage>778</fpage>&#x02013;<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2009.01.009</pub-id>.<pub-id pub-id-type="pmid">19168114</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Seigler</surname><given-names>D. S.</given-names></name>
<article-title>Phytochemistry
of Acacia-sensu lato</article-title>. <source>Biochem. Syst. Ecol.</source>
<year>2003</year>, <volume>31</volume>, <fpage>845</fpage>&#x02013;<lpage>873</lpage>. <pub-id pub-id-type="doi">10.1016/s0305-1978(03)00082-6</pub-id>.</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Gilani</surname><given-names>S. A.</given-names></name>; <name><surname>Khan</surname><given-names>A. M.</given-names></name>; <name><surname>AleemQureshi</surname><given-names>R.</given-names></name>; <name><surname>Sherwani</surname><given-names>S. K.</given-names></name>
<article-title>Ethno-medicinal
treatment of common gastrointestinal disorders by indigenous people
in Pakistan</article-title>. <source>Adv. Biores.</source>
<year>2014</year>, <volume>5</volume>, <fpage>42</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.15515/abr.0976-4585.5.42-49</pub-id>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Al-Fatimi</surname><given-names>M.</given-names></name>; <name><surname>Wurster</surname><given-names>M.</given-names></name>; <name><surname>Schr&#x000f6;der</surname><given-names>G.</given-names></name>; <name><surname>Lindequist</surname><given-names>U.</given-names></name>
<article-title>Antioxidant,
antimicrobial and cytotoxic activities of selected medicinal plants
from Yemen</article-title>. <source>J. Ethnopharmacol.</source>
<year>2007</year>, <volume>111</volume>, <fpage>657</fpage>&#x02013;<lpage>666</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2007.01.018</pub-id>.<pub-id pub-id-type="pmid">17306942</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Kalaivani</surname><given-names>T.</given-names></name>; <name><surname>Mathew</surname><given-names>L.</given-names></name>
<article-title>Free radical scavenging
activity from leaves of Acacia
nilotica (L.) Wild. ex Delile, an Indian medicinal tree</article-title>. <source>Food Chem. Toxicol.</source>
<year>2010</year>, <volume>48</volume>, <fpage>298</fpage>&#x02013;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2009.10.013</pub-id>.<pub-id pub-id-type="pmid">19837122</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Eldeen</surname><given-names>I. M. S.</given-names></name>; <name><surname>Van Staden</surname><given-names>J.</given-names></name>
<article-title>Antimycobacterial
activity of some trees used in South
African traditional medicine</article-title>. <source>S. Afr. J. Bot.</source>
<year>2007</year>, <volume>73</volume>, <fpage>248</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.sajb.2006.09.004</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Bhargava</surname><given-names>A.</given-names></name>; <name><surname>Srivastava</surname><given-names>A.</given-names></name>; <name><surname>Kumbhare</surname><given-names>V.</given-names></name>
<article-title>Antifungal activity of polyphenolic
complex of Acacia nilotica bark</article-title>. <source>Indian For.</source>
<year>1998</year>, <volume>124</volume>, <fpage>292</fpage>&#x02013;<lpage>298</lpage>.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Qasim</surname><given-names>M.</given-names></name>; <name><surname>Abideen</surname><given-names>Z.</given-names></name>; <name><surname>Adnan</surname><given-names>M. Y.</given-names></name>; <name><surname>Ansari</surname><given-names>R.</given-names></name>; <name><surname>Gul</surname><given-names>B.</given-names></name>; <name><surname>Khan</surname><given-names>M.</given-names></name>
<article-title>Traditional ethnobotanical
uses of medicinal plants from coastal
areas</article-title>. <source>J. Coastal Life Med.</source>
<year>2014</year>, <volume>2</volume>, <fpage>22</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Baravkar</surname><given-names>A.</given-names></name>; <name><surname>Kale</surname><given-names>R.</given-names></name>; <name><surname>Patil</surname><given-names>R.</given-names></name>; <name><surname>Sawant</surname><given-names>S. J.</given-names></name>
<article-title>Pharmaceutical and
biological evaluation of formulated cream of methanolic extract of
Acacia nilotica leaves</article-title>. <source>Res. J. Pharm. Technol.</source>
<year>2008</year>, <volume>1</volume>, <fpage>480</fpage>&#x02013;<lpage>483</lpage>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Laskowski</surname><given-names>R. A.</given-names></name>; <name><surname>Rullmannn</surname><given-names>J. A.</given-names></name>; <name><surname>MacArthur</surname><given-names>M. W.</given-names></name>; <name><surname>Kaptein</surname><given-names>R.</given-names></name>; <name><surname>Thornton</surname><given-names>J. M.</given-names></name>
<article-title>AQUA and
PROCHECK-NMR: programs for checking the quality of protein structures
solved by NMR</article-title>. <source>J. Biomol. NMR</source>
<year>1996</year>, <volume>8</volume>, <fpage>477</fpage>&#x02013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1007/bf00228148</pub-id>.<pub-id pub-id-type="pmid">9008363</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Lipinski</surname><given-names>C. A.</given-names></name>
<article-title>Lead- and
drug-like compounds: the rule-of-five revolution</article-title>. <source>Drug Discovery Today: Technol.</source>
<year>2004</year>, <volume>1</volume>, <fpage>337</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id>.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Zhao</surname><given-names>Y. H.</given-names></name>; <name><surname>Abraham</surname><given-names>M. H.</given-names></name>; <name><surname>Le</surname><given-names>J.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Luscombe</surname><given-names>C. N.</given-names></name>; <name><surname>Beck</surname><given-names>G.</given-names></name>; <name><surname>Sherborne</surname><given-names>B.</given-names></name>; <name><surname>Cooper</surname><given-names>I.</given-names></name>
<article-title>Rate-limited steps
of human oral absorption and QSAR studies</article-title>. <source>Pharm.
Res.</source>
<year>2002</year>, <volume>19</volume>, <fpage>1446</fpage>&#x02013;<lpage>1457</lpage>. <pub-id pub-id-type="doi">10.1023/a:1020444330011</pub-id>.<pub-id pub-id-type="pmid">12425461</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Daina</surname><given-names>A.</given-names></name>; <name><surname>Michielin</surname><given-names>O.</given-names></name>; <name><surname>Zoete</surname><given-names>V.</given-names></name>
<article-title>SwissADME: a free web tool to evaluate
pharmacokinetics, drug-likeness and medicinal chemistry friendliness
of small molecules</article-title>. <source>Sci. Rep.</source>
<year>2017</year>, <volume>7</volume>, <fpage>42717</fpage><pub-id pub-id-type="doi">10.1038/srep42717</pub-id>.<pub-id pub-id-type="pmid">28256516</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Mokhnache</surname><given-names>K.</given-names></name>; <name><surname>Madoui</surname><given-names>S.</given-names></name>; <name><surname>Khither</surname><given-names>H.</given-names></name>; <name><surname>Charef</surname><given-names>N.</given-names></name>
<article-title>Drug-Likeness and Pharmacokinetics
of a bis-Phenolic Ligand: Evaluations by Computational Methods</article-title>. <source>Sch. J. Appl. Med. Sci.</source>
<year>2019</year>, <volume>1</volume>, <fpage>167</fpage>&#x02013;<lpage>173</lpage>.</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Ungell</surname><given-names>A.-L.</given-names></name>
<article-title>In Vitro
Absorption Studies and Their Relevance to Absorption from the GI Tract</article-title>. <source>Drug Dev. Ind. Pharm.</source>
<year>1997</year>, <volume>23</volume>, <fpage>879</fpage>&#x02013;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.3109/03639049709148694</pub-id>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name>
<article-title>QSAR Modelling of Rat
Acute Toxicity on the Basis of PASS Prediction</article-title>. <source>Mol. Inf.</source>
<year>2011</year>, <volume>30</volume>, <fpage>241</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201000151</pub-id>.</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Farnsworth</surname><given-names>N. R.</given-names></name>
<article-title>The role
of ethnopharmacology in drug development</article-title>. <source>Ciba
Found. Symp.</source>
<year>1990</year>, <volume>154</volume>, <fpage>2</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/9780470514009.ch2</pub-id>.<pub-id pub-id-type="pmid">2086037</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Chouhan</surname><given-names>G.</given-names></name>; <name><surname>Islamuddin</surname><given-names>M.</given-names></name>; <name><surname>Sahal</surname><given-names>D.</given-names></name>; <name><surname>Afrin</surname><given-names>F.</given-names></name>
<article-title>Exploring the role
of medicinal plant-based immunomodulators for effective therapy of
leishmaniasis</article-title>. <source>Front. Immunol.</source>
<year>2014</year>, <volume>5</volume>, <fpage>193</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00193</pub-id>.<pub-id pub-id-type="pmid">24829566</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Tahir</surname><given-names>A. E.</given-names></name>; <name><surname>Ibrahim</surname><given-names>A. M.</given-names></name>; <name><surname>Satti</surname><given-names>G. M. H.</given-names></name>; <name><surname>Theander</surname><given-names>T. G.</given-names></name>; <name><surname>Kharazmi</surname><given-names>A.</given-names></name>; <name><surname>Khalid</surname><given-names>S. A.</given-names></name>
<article-title>The potential antileishmanial activity
of some Sudanese
medicinal plants</article-title>. <source>Phytother. Res.</source>
<year>1998</year>, <volume>12</volume>, <fpage>576</fpage>&#x02013;<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1099-1573(199812)12:8&#x0003c;576::aid-ptr354&#x0003e;3.0.co;2-#</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Rai</surname><given-names>S. P.</given-names></name>; <name><surname>Prasad</surname><given-names>M. S.</given-names></name>; <name><surname>Singh</surname><given-names>K.</given-names></name>
<article-title>Evaluation
of the antifungal activity
of the potent fraction of hexane extract obtained from the bark of
Acacia nilotica</article-title>. <source>Int. J. Sci. Res.</source>
<year>2014</year>, <volume>3</volume>, <fpage>730</fpage>&#x02013;<lpage>738</lpage>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="book" id="cit34"><person-group person-group-type="allauthors"><name><surname>Ambasta</surname><given-names>S. P.</given-names></name></person-group><source>The Useful Plants
of India</source>; <publisher-name>Publication and Information Directorate,
Council of Scientific &#x00026; Industrial Research</publisher-name>: <publisher-loc>New Delhi, India</publisher-loc>, <year>1994</year>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Sadiq</surname><given-names>M. B.</given-names></name>; <name><surname>Hanpithakpong</surname><given-names>W.</given-names></name>; <name><surname>Tarning</surname><given-names>J.</given-names></name>; <name><surname>Anal</surname><given-names>A. K.</given-names></name>
<article-title>Screening of phytochemicals
and in vitro evaluation of antibacterial and antioxidant activities
of leaves, pods and bark extracts of Acacia nilotica (L.) Del</article-title>. <source>Ind. Crops Prod.</source>
<year>2015</year>, <volume>77</volume>, <fpage>873</fpage>&#x02013;<lpage>882</lpage>. <pub-id pub-id-type="doi">10.1016/j.indcrop.2015.09.067</pub-id>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Borges</surname><given-names>A.</given-names></name>; <name><surname>Ferreira</surname><given-names>C.</given-names></name>; <name><surname>Saavedra</surname><given-names>M. J.</given-names></name>; <name><surname>Sim&#x000f5;es</surname><given-names>M.</given-names></name>
<article-title>Antibacterial
activity and mode of action of ferulic and gallic acids against pathogenic
bacteria</article-title>. <source>Microb. Drug Resist.</source>
<year>2013</year>, <volume>19</volume>, <fpage>256</fpage>&#x02013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1089/mdr.2012.0244</pub-id>.<pub-id pub-id-type="pmid">23480526</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Fatima</surname><given-names>F.</given-names></name>; <name><surname>Khalid</surname><given-names>A.</given-names></name>; <name><surname>Nazar</surname><given-names>N.</given-names></name>; <name><surname>Abdalla</surname><given-names>M.</given-names></name>; <name><surname>Mohomed</surname><given-names>H.</given-names></name>; <name><surname>Toum</surname><given-names>A. M.</given-names></name>; <name><surname>Magzoub</surname><given-names>M.</given-names></name>; <name><surname>Al&#x00131;</surname><given-names>M. S.</given-names></name>
<article-title>In vitro
assessment of anti - cutaneous leishmaniasis activity of some Sudanese
plants</article-title>. <source>Turkiye Parazitol. Derg.</source>
<year>2005</year>, <volume>29</volume>, <fpage>3</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17167733</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Goto</surname><given-names>Y.</given-names></name>; <name><surname>Bhatia</surname><given-names>A.</given-names></name>; <name><surname>Raman</surname><given-names>V. S.</given-names></name>; <name><surname>Vidal</surname><given-names>S. E. Z.</given-names></name>; <name><surname>Bertholet</surname><given-names>S.</given-names></name>; <name><surname>Coler</surname><given-names>R. N.</given-names></name>; <name><surname>Howard</surname><given-names>R. F.</given-names></name>; <name><surname>Reed</surname><given-names>S. G.</given-names></name>
<article-title>Leishmania infantum
sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection
against L. major infection</article-title>. <source>Vaccine</source>
<year>2009</year>, <volume>27</volume>, <fpage>2884</fpage>&#x02013;<lpage>2890</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.079</pub-id>.<pub-id pub-id-type="pmid">19428898</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Baiocco</surname><given-names>P.</given-names></name>; <name><surname>Colotti</surname><given-names>G.</given-names></name>; <name><surname>Franceschini</surname><given-names>S.</given-names></name>; <name><surname>Ilari</surname><given-names>A.</given-names></name>
<article-title>Molecular basis of
antimony treatment in leishmaniasis</article-title>. <source>J. Med.
Chem.</source>
<year>2009</year>, <volume>52</volume>, <fpage>2603</fpage>&#x02013;<lpage>2612</lpage>. <pub-id pub-id-type="doi">10.1021/jm900185q</pub-id>.<pub-id pub-id-type="pmid">19317451</pub-id></mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Ong</surname><given-names>H. B.</given-names></name>; <name><surname>Sienkiewicz</surname><given-names>N.</given-names></name>; <name><surname>Wyllie</surname><given-names>S.</given-names></name>; <name><surname>Fairlamb</surname><given-names>A. H.</given-names></name>
<article-title>Dissecting the metabolic
roles of pteridine reductase 1 in Trypanosoma brucei and Leishmania
major</article-title>. <source>J. Biol. Chem.</source>
<year>2011</year>, <volume>286</volume>, <fpage>10429</fpage>&#x02013;<lpage>10438</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.m110.209593</pub-id>.<pub-id pub-id-type="pmid">21239486</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Scotti</surname><given-names>L.</given-names></name>; <name><surname>Ishiki</surname><given-names>H.</given-names></name>; <name><surname>Mendonca</surname><given-names>F. J. B.</given-names></name>; <name><surname>Silva</surname><given-names>M. S.</given-names></name>; <name><surname>Scotti</surname><given-names>M. T.</given-names></name>
<article-title>In-silico
analyses of natural products on leishmania enzyme targets</article-title>. <source>Mini-Rev. Med. Chem.</source>
<year>2015</year>, <volume>15</volume>, <fpage>253</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.2174/138955751503150312141854</pub-id>.<pub-id pub-id-type="pmid">25769973</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Mielke</surname><given-names>H.</given-names></name>; <name><surname>Strickland</surname><given-names>J.</given-names></name>; <name><surname>Jacobs</surname><given-names>M. N.</given-names></name>; <name><surname>Mehta</surname><given-names>J. M.</given-names></name>
<article-title>Biometrical evaluation
of the performance of the revised OECD Test Guideline 402 for assessing
acute dermal toxicity</article-title>. <source>Regul. Toxicol. Pharmacol.</source>
<year>2017</year>, <volume>89</volume>, <fpage>26</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2017.07.007</pub-id>.<pub-id pub-id-type="pmid">28709685</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Al-Bayati</surname><given-names>N.</given-names></name>; <name><surname>Anwar</surname><given-names>S. A.</given-names></name>; <name><surname>Mahmood</surname><given-names>O. I.</given-names></name>
<article-title>Anti leishmanial
Activity of Methanolic
extract of Juniperus excelsa berries and Acacia nilotica</article-title>. <source>Tikret J. Pharm. Sci.</source>
<year>2016</year>, <volume>11</volume>, <fpage>78</fpage>&#x02013;<lpage>88</lpage>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Tabrez</surname><given-names>S.</given-names></name>; <name><surname>Rahman</surname><given-names>F.</given-names></name>; <name><surname>Ali</surname><given-names>R.</given-names></name>; <name><surname>Alouffi</surname><given-names>A. S.</given-names></name>; <name><surname>Akand</surname><given-names>S. K.</given-names></name>; <name><surname>Alshehri</surname><given-names>B. M.</given-names></name>; <name><surname>Alshammari</surname><given-names>F. A.</given-names></name>; <name><surname>Alam</surname><given-names>A.</given-names></name>; <name><surname>Alaidarous</surname><given-names>M. A.</given-names></name>; <name><surname>Banawas</surname><given-names>S.</given-names></name>; <name><surname>Dukhyil</surname><given-names>A. A. B.</given-names></name>; <name><surname>Rub</surname><given-names>A.</given-names></name>
<article-title>Cynaroside inhibits
Leishmania donovani UDP-galactopyranose mutase and induces reactive
oxygen species to exert antileishmanial response</article-title>. <source>Biosci. Rep.</source>
<year>2021</year>, <volume>41</volume>, <fpage>BSR20203857</fpage><pub-id pub-id-type="doi">10.1042/BSR20203857</pub-id>.<pub-id pub-id-type="pmid">33367614</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Dallakyan</surname><given-names>S.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name>
<article-title>Small-molecule library screening
by docking with PyRx</article-title>. <source>Methods Mol. Biol.</source>
<year>2015</year>, <volume>1263</volume>, <fpage>243</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-2269-7_19</pub-id>.<pub-id pub-id-type="pmid">25618350</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Trott</surname><given-names>O.</given-names></name>; <name><surname>Olson</surname><given-names>A. J.</given-names></name>
<article-title>AutoDock Vina: improving
the speed and accuracy of
docking with a new scoring function, efficient optimization, and multithreading</article-title>. <source>J. Comput. Chem.</source>
<year>2010</year>, <volume>31</volume>, <fpage>455</fpage>&#x02013;<lpage>461</lpage>. <pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id>.<pub-id pub-id-type="pmid">19499576</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Rahman</surname><given-names>F.</given-names></name>; <name><surname>Tabrez</surname><given-names>S.</given-names></name>; <name><surname>Ali</surname><given-names>R.</given-names></name>; <name><surname>Alqahtani</surname><given-names>A. S.</given-names></name>; <name><surname>Ahmed</surname><given-names>M. Z.</given-names></name>; <name><surname>Rub</surname><given-names>A.</given-names></name>
<article-title>Molecular docking analysis
of rutin
reveals possible inhibition of SARS-CoV-2 vital proteins</article-title>. <source>J. Tradit. Complementary Med.</source>
<year>2021</year>, <volume>11</volume>, <fpage>173</fpage><pub-id pub-id-type="doi">10.1016/j.jtcme.2021.01.006</pub-id>.</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Kashif</surname><given-names>M.</given-names></name>; <name><surname>Tabrez</surname><given-names>S.</given-names></name>; <name><surname>Husein</surname><given-names>A.</given-names></name>; <name><surname>Arish</surname><given-names>M.</given-names></name>; <name><surname>Kalaiarasan</surname><given-names>P.</given-names></name>; <name><surname>Manna</surname><given-names>P. P.</given-names></name>; <name><surname>Subbarao</surname><given-names>N.</given-names></name>; <name><surname>Akhter</surname><given-names>Y.</given-names></name>; <name><surname>Rub</surname><given-names>A.</given-names></name>
<article-title>Identification
of novel inhibitors against UDP-galactopyranose mutase to combat leishmaniasis</article-title>. <source>J. Cell. Biochem.</source>
<year>2018</year>, <volume>119</volume>, <fpage>2653</fpage>&#x02013;<lpage>2665</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.26433</pub-id>.<pub-id pub-id-type="pmid">29058760</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Kashif</surname><given-names>M.</given-names></name>; <name><surname>Hira</surname><given-names>S. K.</given-names></name>; <name><surname>Upadhyaya</surname><given-names>A.</given-names></name>; <name><surname>Gupta</surname><given-names>U.</given-names></name>; <name><surname>Singh</surname><given-names>R.</given-names></name>; <name><surname>Paladhi</surname><given-names>A.</given-names></name>; <name><surname>Khan</surname><given-names>F. I.</given-names></name>; <name><surname>Rub</surname><given-names>A.</given-names></name>; <name><surname>Manna</surname><given-names>P. P.</given-names></name>
<article-title>In silico
studies and evaluation of antiparasitic role of a novel pyruvate phosphate
dikinase inhibitor in Leishmania donovani infected macrophages</article-title>. <source>Int. J. Antimicrob. Agents</source>
<year>2019</year>, <volume>53</volume>, <fpage>508</fpage>&#x02013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.12.011</pub-id>.<pub-id pub-id-type="pmid">30599242</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Zimmermann</surname><given-names>L.</given-names></name>; <name><surname>Stephens</surname><given-names>A.</given-names></name>; <name><surname>Nam</surname><given-names>S.-Z.</given-names></name>; <name><surname>Rau</surname><given-names>D.</given-names></name>; <name><surname>K&#x000fc;bler</surname><given-names>J.</given-names></name>; <name><surname>Lozajic</surname><given-names>M.</given-names></name>; <name><surname>Gabler</surname><given-names>F.</given-names></name>; <name><surname>S&#x000f6;ding</surname><given-names>J.</given-names></name>; <name><surname>Lupas</surname><given-names>A. N.</given-names></name>; <name><surname>Alva</surname><given-names>V.</given-names></name>
<article-title>A Completely Reimplemented
MPI Bioinformatics
Toolkit with a New HHpred Server at its Core</article-title>. <source>J. Mol. Biol.</source>
<year>2018</year>, <volume>430</volume>, <fpage>2237</fpage>&#x02013;<lpage>2243</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2017.12.007</pub-id>.<pub-id pub-id-type="pmid">29258817</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Sali</surname><given-names>A.</given-names></name>; <name><surname>Blundell</surname><given-names>T. L.</given-names></name>
<article-title>Comparative protein
modelling by satisfaction of spatial
restraints</article-title>. <source>J. Mol. Biol.</source>
<year>1993</year>, <volume>234</volume>, <fpage>779</fpage>&#x02013;<lpage>815</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1993.1626</pub-id>.<pub-id pub-id-type="pmid">8254673</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>O&#x02019;Boyle</surname><given-names>N. M.</given-names></name>; <name><surname>Banck</surname><given-names>M.</given-names></name>; <name><surname>James</surname><given-names>C. A.</given-names></name>; <name><surname>Morley</surname><given-names>C.</given-names></name>; <name><surname>Vandermeersch</surname><given-names>T.</given-names></name>; <name><surname>Hutchison</surname><given-names>G. R.</given-names></name>
<article-title>Open Babel: An open chemical toolbox</article-title>. <source>J. Cheminf.</source>
<year>2011</year>, <volume>3</volume>, <fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id>.</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Rapp&#x000e9;</surname><given-names>A. K.</given-names></name>; <name><surname>Casewit</surname><given-names>C. J.</given-names></name>; <name><surname>Colwell</surname><given-names>K. S.</given-names></name>; <name><surname>Goddard</surname><given-names>W. A.</given-names><suffix>III</suffix></name>; <name><surname>Skiff</surname><given-names>W. M.</given-names></name>
<article-title>UFF, a full periodic
table force field for molecular
mechanics and molecular dynamics simulations</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1992</year>, <volume>114</volume>, <fpage>10024</fpage>&#x02013;<lpage>10035</lpage>. <pub-id pub-id-type="doi">10.1021/ja00051a040</pub-id>.</mixed-citation></ref></ref-list></back></article>